Magnetic resonance contrast enhancement neovasculature with α(v)β3-targeted nanoparticles

Stasia A. Anderson, Randall K. Rader, William F. Westlin, Christopher Null, Dowdy Jackson, Gregory M. Lanza, Samuel A. Wickline, John J. Kotyk

Research output: Contribution to journalArticlepeer-review

259 Scopus citations

Abstract

Site-directed contrast enhancement of angiogenic vessels in vivo was demonstrated using antibody targeting of an MRI contrast agent to the α(v)β3 integrin, a molecular marker characteristic of angiogenic endothelium. The agent was tested in a rabbit corneal micropocket model, in which neovasculature is induced in the cornea using basic fibroblast growth factor. The targeted contrast agent consists of Gd-perfluorocarbon nano-particles linked to α(v)β3 integrin antibody DM101. The animal group receiving the targeted contrast agent displayed a 25% increase in the average MR signal intensity after 90 min. Control groups in which the nanoparticles are either used alone, linked to an isotype-matched antibody, or linked to DM101 and administered following receptor blocking did not display MR contrast enhancement at similar dose levels. These findings indicate that the antibody-targeted agent enhances MR signal intensity in the capillary bed in a corneal micropocket model of angiogenesis, and is selectively retained within the angiogenic region via specific interaction with the α(v)β3 epitope. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)433-439
Number of pages7
JournalMagnetic resonance in medicine
Volume44
Issue number3
DOIs
StatePublished - 2000

Keywords

  • Angiogenesis
  • Antibody targeting
  • Contrast agent
  • Corneal micropocket
  • MRI

Fingerprint Dive into the research topics of 'Magnetic resonance contrast enhancement neovasculature with α(v)β<sub>3</sub>-targeted nanoparticles'. Together they form a unique fingerprint.

Cite this